Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target - PubMed (original) (raw)

Review

Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target

Andrew Zalewski et al. Arterioscler Thromb Vasc Biol. 2005 May.

Abstract

The development of atherosclerotic vascular disease is invariably linked to the formation of bioactive lipid mediators and accompanying vascular inflammation. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that is produced by inflammatory cells, co-travels with circulating low-density lipoprotein (LDL), and hydrolyzes oxidized phospholipids in LDL. Its biological role has been controversial with initial reports purporting atheroprotective effects of Lp-PLA2 thought to be a consequence of degrading platelet-activating factor and removing polar phospholipids in modified LDL. Recent studies, however, focused on pro-inflammatory role of Lp-PLA2 mediated by products of the Lp-PLA2 reaction (lysophosphatidylcholine and oxidized nonesterified fatty acids). These bioactive lipid mediators, which are generated in lesion-prone vasculature and to a lesser extent in the circulation (eg, in electronegative LDL), are known to elicit several inflammatory responses. The proinflammatory action of Lp-PLA2 is also supported by a number of epidemiology studies suggesting that the circulating level of the enzyme is an independent predictor of cardiovascular events, despite some attenuation of the effect by inclusion of LDL, the primary carrier of Lp-PLA2, in the analysis. These observations provide a rationale to explore whether inhibiting Lp-PLA2 activity and consequent interference with the formation of bioactive lipid mediators will abrogate inflammation associated with atherosclerosis, produce favorable changes in intermediate cardiovascular end points (eg, biomarkers, imaging, and endothelial function), and ultimately reduce cardiovascular events in high-risk patients.

PubMed Disclaimer

Cited by

Association of Lp-PLA2 Mass and Aysmptomatic Intracranial and Extracranial Arterial Stenosis in Hypertension Patients.
Wang Y, Zhang J, Qian Y, Tang X, Ling H, Chen K, Gao P, Zhu D. Wang Y, et al. PLoS One. 2015 Jun 22;10(6):e0130473. doi: 10.1371/journal.pone.0130473. eCollection 2015. PLoS One. 2015. PMID: 26098634 Free PMC article.
Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers.
Ostadal P, Vondrakova D, Kruger A, Janotka M, Psotova H, Prucha M. Ostadal P, et al. Lipids Health Dis. 2012 Nov 10;11:153. doi: 10.1186/1476-511X-11-153. Lipids Health Dis. 2012. PMID: 23140470 Free PMC article.
Lipoprotein-associated phospholipase A(2) : review of its role as a marker and a potential participant in coronary endothelial dysfunction.
Lavi S, Lavi R, McConnell JP, Lerman LO, Lerman A. Lavi S, et al. Mol Diagn Ther. 2007;11(4):219-26. doi: 10.1007/BF03256243. Mol Diagn Ther. 2007. PMID: 17705576 Review.
Increased Lipoprotein-associated phospholipase A2 activity portends an increased risk of resistant hypertension.
Li Z, Liu J, Shen Y, Zeng F, Zheng D. Li Z, et al. Lipids Health Dis. 2016 Jan 22;15:15. doi: 10.1186/s12944-016-0184-9. Lipids Health Dis. 2016. PMID: 26801405 Free PMC article.
Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit.
Brites F, Martin M, Guillas I, Kontush A. Brites F, et al. BBA Clin. 2017 Aug 19;8:66-77. doi: 10.1016/j.bbacli.2017.07.002. eCollection 2017 Dec. BBA Clin. 2017. PMID: 28936395 Free PMC article. Review.

Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target - PubMed (original) (raw)